Výsledky vyhledávání - "Chantal Le Guellec"

Akademický článek

Cost-Effectiveness of UGT1A1*28 Genotyping in Preventing Severe Neutropenia Following FOLFIRI Therapy in Colorectal Cancer.

Autor: Solen Pichereau, Anne Le Louarn, Thierry Lecomte, Hélène Blasco, Chantal Le Guellec, Hélène Bourgoin

Publikováno v: Journal of Pharmacy & Pharmaceutical Sciences, Vol 13, Iss 4 (2011)

PURPOSE: Functional polymorphisms of the UGT1A1 gene, particularly the UGT1A1*28 variant, are associated with the severity of the bone marrow suppression in patients with metastatic colorectal cancer receiving irinotecan. This study assesses the cost

Externí odkaz: https://doaj.org/article/946a8809f78846f1b984c79cf85b82df

Zobrazit plný text záznamu

Assessing the Metabolic Effects of Calcineurin Inhibitors in Renal Transplant Recipients by Urine Metabolic Profiling

Autor: Jean-Michel Halimi, Chantal Le Guellec, Binta Diémé, Lydie Nadal-Desbarat, Patrick Emond, Matthias Büchler, Hélène Blasco

Publikováno v: Transplantation. 98:195-201

BACKGROUND Biomarkers that can predict graft function and/or renal side effects of calcineurin inhibitors (CNI) at each stage of treatment in kidney transplantation are still lacking. We report the first untargeted GC-MS-based metabolomic study on ur

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf4b11f44d302f20a443ed881f0ebffb
https://doi.org/10.1097/tp.0000000000000039

Zobrazit plný text záznamu

Urinary coproporphyrin I/(I + III) ratio as a surrogate for MRP2 or other transporter activities involved in methotrexate clearance

Autor: Sylvain Choquet, Chantal Le Guellec, Severine Lissandre, Caroline Houillier, Isabelle Benz-de Bretagne, Amélie Le Gouge, Noël Zahr, Khê Hoang-Xuan, Emmanuel Gyan, Jean-Sébastien Hulot

Publikováno v: British Journal of Clinical Pharmacology. 78:329-342

Aims The urinary coproporphyrin I/(I + III) ratio may be a surrogate for MRP2 activity. We conducted a prospective study in patients receiving methotrexate (MTX) to examine the relationship between this ratio and the pharmacokinetics of a MRP2 substr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b9d8d94db2a378df0acc935279a2e63d
https://doi.org/10.1111/bcp.12326

Zobrazit plný text záznamu

Intérêt du génotypage de l’UGT1A1 dans le cadre du traitement des cancers digestifs par irinotécan

Autor: Fabienne Thomas, Jean-Christophe Boyer, Laurent Philibert, Nicolas Picard, Marie-Pierre Gaub, Marie-Christine Etienne-Grimaldi, Marie-Claude Gagnieu, Sylvie Quaranta, Franck Broly, Cécile Ged, François Ghiringhelli, Valérie Le Morvan, Delphine Poncet, Chantal Le Guellec, Marie-Anne Loriot, Régis Bouquié

Publikováno v: Bulletin du Cancer. 101:533-553

Resume L’irinotecan est un agent cytotoxique largement utilise dans le traitement des cancers colorectaux avances. Son activite anticancereuse depend de sa bioactivation en metabolite SN38 et son elimination se fait sous forme glucuronoconjuguee pa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::042b3a0d89ba362e2dded4a396b4498b
https://doi.org/10.1684/bdc.2014.1933

Zobrazit plný text záznamu

Population pharmacokinetics of rituximab with or without plasmapheresis in kidney patients with antibody-mediated disease

Autor: Anaïs Grand, Chantal Le Guellec, Thierry Lafont, Florent Puisset, Frédérique Haberer, Hélène Blasco, Etienne Chatelut, Melanie White-Koning, Nassim Kamar, Lionel Rostaing, Antoine Huart, Jacques Pourrat

Publikováno v: British Journal of Clinical Pharmacology. 76:734-740

Aims Both rituximab and plasmapheresis can be associated in the treatment of immune-mediated kidney diseases. The real impact of plasmapheresis on rituximab pharmacokinetics is unknown. The aim of this study was to compare rituximab pharmacokinetics

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::bf90cf44414a7dc08bd46c570539d9ae
https://doi.org/10.1111/bcp.12098

Zobrazit plný text záznamu

Irreversible hepatotoxicity after administration of trabectedin to a pleiomorphic sarcoma patient with a rare ABCC2 polymorphism: a case report

Autor: Isabelle Hennebelle, Christine Chevreau, Sarah Bétrian, Etienne Chatelut, Sophie Le Guellec, Fabienne Thomas, Anne-Pascale Laurenty, Chantal Le Guellec

Publikováno v: Pharmacogenomics. 14:1389-1396

We describe here the case of a 60-year old male patient treated for an extensive local progression of a pleiomorphic sarcoma on the right tibial crest with second-line trabectedin. Two cycles were administrated before a major liver toxicity was retri

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b82aa0f2c81537938afb8a1e2972a7c
https://doi.org/10.2217/pgs.13.124

Zobrazit plný text záznamu

A New Rapid and Sensitive LC-MS Assay for the Determination of Sorafenib in Plasma: Application to a Patient Undergoing Hemodialysis

Autor: Christine Bobin-Dubigeon, Chantal Le Guellec, Alexandra Heurgue-Berlot, Marie-Bernadette Amiand, Olivier Bouché, Jean-Marie Bard

Publikováno v: Therapeutic Drug Monitoring. 33:705-710

A simple liquid chromatography-mass spectrometry method was developed and validated for quantification of sorafenib (Nexavar) in human plasma. After a solid-phase extraction procedure, the separation was performed within 2 minutes using an isocratic

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f6a96faf71f4a5feaa6d0fd1538f1aa1
https://doi.org/10.1097/ftd.0b013e3182357891

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání